Home / Companies / JAZZ / Catalysts / Page 2 Catalysts · JAZZ · CIK 1232524 · page 2 of 2 JAZZ catalysts and FDA events, page 2. Updated November 16, 2026 Snapshot 20261116T222116Z Built 2026-11-16 22:21 UTC
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on JAZZ PDUFA dates and upcoming catalysts . This page continues the list.
Past catalysts and FDA decisions (continued) Date Drug Company Event Indication Status Source August 5, 2025 — JAZZ Earnings — Completed SEC 8-K Exhibit 99.1 Aug 2025Month disclosed Modeyso (dordaviprone) JAZZ FDA approval — Approved SEC 8-K Exhibit 99.1 Jun 2025Month disclosed Tecentriq® (atezolizumab) JAZZ Label expansion — Approved SEC Form 10-Q May 6, 2025 — JAZZ Earnings — Completed SEC 8-K Exhibit 99.1 February 25, 2025 Ziihera® (zanidatamab) JAZZ FDA approval with previously treated, unresectable or metastatic HER2-positive Approved SEC 8-K Exhibit 99.1 February 25, 2025 — JAZZ Earnings — Completed SEC 8-K Exhibit 99.1 1H 2025Half-year disclosed Tecentriq® (atezolizumab) JAZZ NDA/BLA submission — Scheduled SEC 8-K Exhibit 99.1 1H 2025Half-year disclosed Zepzelca (lurbinectedin) JAZZ NDA/BLA submission — Scheduled SEC 8-K Exhibit 99.1 2025Year disclosed JZP441 JAZZ Trial start — Scheduled SEC Form 10-K 1H 2025Half-year disclosed GEA-01 JAZZ NDA/BLA submission — Scheduled SEC 8-K Exhibit 99.1 November 20, 2024 Ziihera® (zanidatamab) JAZZ FDA approval with previously treated, unresectable or metastatic HER2-positive Approved SEC Form 8-K Oct 2024Month disclosed Zepzelca (lurbinectedin) JAZZ Topline readout — Met primary endpoint SEC Form 10-Q Oct 2024Month disclosed Tecentriq® (atezolizumab) JAZZ Topline readout — Met primary endpoint SEC Form 10-Q Oct 2024Month disclosed — JAZZ Topline readout — Met primary endpoint SEC Form 10-Q Nov 2022Month disclosed suvecaltamide (JZP385) JAZZ Trial start Parkinson's disease tremor Completed SEC Form 10-K August 12, 2021 Xywav (calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate) JAZZ Label expansion — Approved openFDA Drugs@FDA July 21, 2020 Xywav (calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate) JAZZ FDA approval — Approved openFDA Drugs@FDA June 15, 2020 Zepzelca (lurbinectedin) JAZZ FDA approval — Approved openFDA Drugs@FDA
FDA calendar PDUFA dates PDUFA calendar AdCom calendar FDA approvals today CRL tracker PDUFA outcomes dataset Indications Every catalyst is quoted from JAZZ’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.